TriSalus Life Sciences Files 8-K on Financials

TL;DR

TriSalus Life Sciences dropped an 8-K on Jan 23rd detailing their financials. Check it out.

AI Summary

TriSalus Life Sciences, Inc. filed an 8-K on January 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Westminster, Colorado. The company was formerly known as MedTech Acquisition Corp before changing its name on September 30, 2020.

Why It Matters

This 8-K filing provides an update on TriSalus Life Sciences' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant negative developments.

Key Players & Entities

• TriSalus Life Sciences, Inc. (company) — Registrant
• January 23, 2025 (date) — Date of Report
• MedTech Acquisition Corp (company) — Former Company Name
• September 30, 2020 (date) — Date of Name Change
• Delaware (jurisdiction) — State of Incorporation
• Westminster, Colorado (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common stock, $0.0001 par value TLSI Nasdaq Global Market W
• $11.50 — 's common stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Market

Filing Documents

• tlsi-20250123.htm (8-K) — 28KB
• q42024earningsrelease-prex.htm (EX-99.1) — 20KB
• image.jpg (GRAPHIC) — 20KB
• 0001826667-25-000007.txt ( ) — 245KB
• tlsi-20250123.xsd (EX-101.SCH) — 2KB
• tlsi-20250123_def.xml (EX-101.DEF) — 16KB
• tlsi-20250123_lab.xml (EX-101.LAB) — 27KB
• tlsi-20250123_pre.xml (EX-101.PRE) — 16KB
• tlsi-20250123_htm.xml (XML) — 4KB

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. On January 23, 2025, TriSalus Life Sciences, Inc. (the "Company") announced certain of its preliminary unaudited financial results for the year and quarter ended December 31, 2024 in the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after today's date, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release date January 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2025 TriSalus Life Sciences, Inc. By: /s/ James Young Name: James Young Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR